Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

Published:2023-06-29 Issue:13 Volume:66 Page:8822-8843
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Han Xin¹²^ORCID,Zhao Lijie¹²,Xiang Weiguo¹²,Miao Bukeyan¹²,Qin Chong¹²^ORCID,Wang Mi¹²,Xu Tianfeng¹²^ORCID,McEachern Donna¹²,Lu Jianfeng¹²,Wang Yu¹²,Metwally Hoda¹²,Yang Chao-Yie¹²^ORCID,Kirchhoff Paul D.¹²,Wang Lu³,Matvekas Aleksas³,Takyi-Williams John³,Wen Bo³,Sun Duxin³^ORCID,Ator Mark⁴,Mckean Robert⁴,Wang Shaomeng¹²⁵⁶^ORCID

Affiliation:

1. The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

3. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Oncopia Therapeutics Inc, 2 West Liberty Blvd., Malvern, Pennsylvania 19355, United States

5. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States

6. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Proteovant Therapeutics Inc

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00405

Reference43 articles.

1. Prostate cancer

2. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016

3. Role of Androgen Receptor in Prostate Cancer: A Review

4. Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting

5. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer;Cancers;2024-02-04

2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders;European Journal of Medicinal Chemistry;2024-02

3. Current advances and development strategies of orally bioavailable PROTACs;European Journal of Medicinal Chemistry;2023-12

4. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer;Journal of Medicinal Chemistry;2023-09-08

5. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity;Journal of Medicinal Chemistry;2023-08-30